Pfizer's Phase 3 Study Of Abrocitinib Shows Positive Top-Line Results

Pfizer Inc. (PFE) announced Wednesday positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD). The study also achieved all co-primary and secondary endpoints.

from RTT - Biotech http://bit.ly/30ofCBJ
via IFTTT